Biomarin Pharmaceutical (BMRN) Accounts Payables (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Accounts Payables came in at $793.2 million in Q1 2026, up 26.26% YoY from $628.2 million in Q1 2025, and up 4.5% on a QoQ basis from $759.0 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Accounts Payables (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Accounts Payables data on file, last reported at $793.2 million in Q1 2026.
- Quarterly Accounts Payables rose 26.26% year-over-year to $793.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $793.2 million (up 26.26% YoY) and the FY2025 annual result came in at $759.0 million, up 25.05% from the prior year.
- Accounts Payables rose to $793.2 million in Q1 2026, from $759.0 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $798.4 million in Q3 2025 to a low of $426.4 million in Q1 2022.
- A 5-year average of $625.1 million and a median of $607.0 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables soared 40.29% — and 2024, when it dropped 11.15%.
- Tracing BMRN's Accounts Payables over 5 years: stood at $573.0 million in 2022, then rose by 19.23% to $683.1 million in 2023, then retreated by 11.15% to $607.0 million in 2024, then gained by 25.05% to $759.0 million in 2025, then increased by 4.5% to $793.2 million in 2026.
- The last three Accounts Payables figures came in at $793.2 million (Q1 2026), $759.0 million (Q4 2025), and $798.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 1.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 Bn |
| Mar 31, 2026 | 793.15 Mn |
| Dec 31, 2025 | 759.03 Mn |
| Sep 30, 2025 | 798.44 Mn |
| Jun 30, 2025 | 684.25 Mn |
| Mar 31, 2025 | 628.21 Mn |
| Dec 31, 2024 | 606.99 Mn |
| Sep 30, 2024 | 715.66 Mn |
| Jun 30, 2024 | 572.50 Mn |
| Mar 31, 2024 | 593.54 Mn |
| Dec 31, 2023 | 683.15 Mn |
| Sep 30, 2023 | 669.83 Mn |
| Jun 30, 2023 | 597.23 Mn |
| Mar 31, 2023 | 598.23 Mn |
| Dec 31, 2022 | 572.96 Mn |
| Sep 30, 2022 | 492.72 Mn |
| Jun 30, 2022 | 434.77 Mn |
| Mar 31, 2022 | 426.42 Mn |
| Dec 31, 2021 | 498.27 Mn |
| Sep 30, 2021 | 466.71 Mn |